Pharmaceutical Technology11h
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 ...
Pharmaceutical Technology11h
Risk adjusted net present value: What is the current valuation of Roche’s CT-388?
It is administered through subcutaneous route. The drug candidate acts by targeting glucagon like peptide 1 receptor (GLP-1R) and gastric inhibitory polypeptide (GIP). It is being developed based on ...
How we got to a global obesity epidemic and how GLP-1 is a game-changer
The global obesity epidemic represents one of the most pressing public health challenges of our time. With nearly ...
AOL20h
Semaglutide Weight Loss Drug Nausea: 8 Tips for Relieving It
But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide-1 receptor agonists) — the ...
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update
Tv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 22,500 shares, a decrease ...